Welcome to the e-CCO Library!

P732: Impact of different types of physical activity in inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gofflot, A.(1)*;Monin, L.(2);Seidel, L.(3);Reenaers, C.(2);Kropp, S.(2);Van Kemseke, C.(2);Latour, P.(2);Forthomme, B.(1);Croisier, J.L.(1);Louis, E.(2);Vieujean, S.(2);
Created: Friday, 14 July 2023, 11:12 AM
P733 The influence of concomitant familial Mediterranean fewer on Crohn’s disease course: Data from an FMF endemic area
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Yuksel1,2, S. Kilincalp3, Y. Coskun3, H. Akinci3, M. Hamamci3

Created: Thursday, 30 January 2020, 10:12 AM
P733: Comparative Analysis of Monotherapy and Combination Biological Therapy for Crohn’s disease and ulcerative colitis: Results from a Multi-Country Study in Europe
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Robinson*1, R. Bergman2, P. Collins1, C. Karki2, Y. Lu2

Created: Friday, 22 February 2019, 9:41 AM
P733: Novelties of COVID-19 vaccination beyond efficacy: Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Resál, T.(1)*;Horváth, M.(2);Bacsur, P.(1);Szántó, K.(1);Rutka, M.(1);Bálint, A.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Fekete, J.(3);Miheller, P.(2);Molnár, T.(1);
Created: Friday, 14 July 2023, 11:12 AM
P733: Past history of bariatric surgery associated with increased risk of new onset inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ungaro R.*1, Chang H.2, Roque Ramos L.1, Fausel R.1, Torres J.1, Colombel J.-F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P733: Serum interleukin-6 level predicts future outcomes of infliximab for ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

Y. Nishida*, S. Hosomi, T. Yukawa, K. Otani, Y. Nagami, F. Tanaka, K. Taira, N. Kamata, H. Yamagami, T. Tanigawa, T. Watanabe, Y. Fujiwara

Created: Thursday, 21 February 2019, 9:14 AM
P734 Should we have a higher threshold for anti-TNF serum levels in Crohn’s disease patients with perianal disease?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Arieira1,2,3, F. Dias de Castro1,2,3, T. Cúrdia Gonçalves1,2,3, M.J. Moreira1,2,3, J. Cotter1,2,3

Created: Thursday, 30 January 2020, 10:12 AM
P734: A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn's disease prognosis - a prospective study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Magro, F.(1);Estevinho, M.M.(2)*;Catalano, G.(3);Patita, M.(4);Arroja, B.(5);Lago, P.(6);Rosa, I.(7);Tavares-de-Sousa, H.(8);Ministro, P.(9);Roseira, J.(8);Cancela, E.(9);Sousa, P.(9);Portela, F.(10);Correia, L.(11);Moreira, P.(12);Santiago, M.(13);Dias, S.(13);Afonso, J.(14);Danese, S.(15);Peyrin-Biroulet, L.(16);Dias, C.C.(17);
Created: Friday, 14 July 2023, 11:12 AM
P734: Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of life
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Duricová1*, E. Dvorakova1, J. Kozeluhova2, P. Kohout3, K. Mitrova4, M. Durilova5, K. Zarubova4, O. Hradsky4, J. Bronsky4, N. Hradska6, E. Bronska6, N. Machkova1, V. Hruba1, M. Bortlik1, M. Lukas1, K. Malickova1, M. Lukas1

Created: Thursday, 21 February 2019, 9:14 AM
P734: Combining endoscopic and histological activity for predicting response to treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Di Ruscio*1, A. Variola1, A. Geccherle1, G. Lunardi2, P. Castelli3, G. Zamboni3, R. Riddell4

Created: Friday, 22 February 2019, 9:41 AM
P734: The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Shah S.C.*1, Khalili H.2, Gower-Rousseau C.3, Olén O.4, Benchimol E.5, Lynge E.6, Nielsen K.7, Ahn H.8, Brassard P.9, Vutcovici M.9, Bitton A.9, Bernstein C.10, Leddin D.11, Tamim H.11, Aniwan S.12, Chen C.-Y.13, Stefánsson T.14, Loftus Jr. E.V.15, Moum B.16, Tang W.17, Ng S.17, Gearry R.18, Sincic B.19, Bell S.20, Lakatos P.L.21, Végh Z.21, Ott C.22, Kaplan G.23, Burisch J.24, Colombel J.-F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P735 Comparative assessment of probiotics and standard therapies for mild to moderate ulcerative colitis: A systematic review and network meta-analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Paschos1, A. Katsoula2, K. Malandris2, M. Sarigianni2, E. Athanasiadou2, A. Koukoufiki2, O. Giouleme3, A. Tsapas2

Created: Thursday, 30 January 2020, 10:12 AM
P735: Immunogenicity differences between anti-TNF drugs
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. M. Gómez Espín*1, I. Nicolás de Prado1, C. Iniesta Navalón2, L. Rentero Redondo2, M. Gil Candel2, J. J. Martínez Crespo1

Created: Friday, 22 February 2019, 9:41 AM
P735: Incidence of venous thromboembolic complications in controlled trials of inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Vermeire1*, M. Crowther2, V. Pradhan3, A. Banerjee3, F. Cataldi4, K. Gorelick5

Created: Thursday, 21 February 2019, 9:14 AM
P735: Indirect burden of patients with moderate inflammatory bowel disease in Uppsala County Council, Sweden: a retrospective study using real-world data
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hellström P.M.*1, Stålhammar J.2, Beydogan H.3, Huetson P.3, Skup M.4, Agréus L.5

Created: Wednesday, 20 February 2019, 10:36 AM
P735: Real-life experience with the use of Tofacitinib in Colombian patients with moderate to severe Ulcerative Colitis: a descriptive study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Parra Izquierdo, L.V.(1)*;Frías-Ordoñez, J.(2); Márquez, J.R.(3);Juliao-Baños , F.(4);Galindo, P.(5);Cuadros, C.(6);Rojas, C.(7);Rojas, N.(7);Ardila, O.(8);Tovar-Fierro , G.(9);García-Duperly, R.(10);Gil Parada, F.L.(11);Imbeth Acosta, P.L.(12);Puentes, F.E.(13);Galiano de Sánchez, M.T.(14);Hani de Ardila, A.(15); Flórez-Sarmiento, C.(1);
Created: Friday, 14 July 2023, 11:12 AM
P736 Utility of infliximab serum concentration in inflammatory bowel disease treatment in real world practice at Hospital Universitario de Canarias
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Carrillo Palau1, I. Alonso-Abreu1, L. Ramos-Lopez1, G.N. Fernando2, N. Hernandez Alvarez-Buylla1, A. Hernandez-Perez1, S. Medina-Chico1, E. Quintero1

Created: Thursday, 30 January 2020, 10:12 AM
P736: Characteristics of polymeric formula and mode of delivery of exclusive enteral nutrition have no effect on disease outcome and weight gain in children with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Hojsak*1, I. Trivic1, S. Sila1, K. Matic2, Z. Misak1, S. Kolacek1

Created: Friday, 22 February 2019, 9:41 AM
P736: Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1)*;Louis , E.(2);Hisamatsu, T.(3);Jamoul, C.(4);Santermans, E.(4);Harris , K.(5);de Haas, A.(6);Oortwijn , A.(7);Feagan , B.(8);
Created: Friday, 14 July 2023, 11:12 AM
P736: Point-of-care infliximab quantification in inflammatory bowel disease in daily practice
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.P. Costa Santos*, C. Palmela, C. Gouveia, C. Fidalgo, L. Glória, M. Cravo, J. Torres

Created: Thursday, 21 February 2019, 9:14 AM